Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer
China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...
Jemincare
Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment
China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...
Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904
US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...
Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...
Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China
Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...
Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China
Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US
China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology
Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...
Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors
China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...
Jemincare’s Avatrombopag Market Filing Accepted for Review by China’s CDE
China-based Jiangxi Jemincare Group has announced that its market filing for avatrombopag maleate (20mg) has...
Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study
China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...
Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...
Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech
China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....